CHAPTER 8 - BIBLIOGRAPHY

BIBLIOGRAPHY

1. ww w.irs.gov

2. (APBN 2004): Asia Pacific Biotech News( APBN), Vol. 8 , No. 5 ,

pp. 272.

3. Chervenak, Mathew (May - June 2005): An Emerging Biotech

Giant ? - Opportunities for Well Informed Foreign Investors

Abound in China’s Growing Biotech Sector, China Business

Review , pp. 48 - 53.

4. Palnitkar, Utkarsh (January 2005): Growth of Indian Biotech

Companies in the Context of International Biotechnology

Industry, Journal of Commercial Biotechnology, V ol. 11, No. 2,

pp. 146 -154 .

5. Mukherjee, P.N (2006): Holistic Management System for World

Class Performance and Leadership, Total Quality Management,

pp.137.

6. B, Mahadevan (September 1998): Principles of World Class

Manufacturing, The Management Accountant, pp.645 - 649.

7. Kirchhoff, Marc; Schiereck, Dirk (2011): Determinants of M&A

Success in the Pharmaceutical and Biotechnological Industry ;

The IUP Journal of Business Strategy, Vol. VIII, No. 1, pp. 25- 50.

8. Conklin, David (2011): Global Environment of Business, Investing

in New Technologies, Chapter 6, p p .ll l -136 .

9. Gobble, Mary Anne (March—April 2011): Intellectual Property

Cases Reshaping Biotech, Research and Technology Management,

pp. 5 - 6 .

10. Festel, Gunter; H. De Cleyn, Sven; Boutellier, Roman ; Braet,

Johan ( Jan - Feb 2011): Optimizing The R & D Process Using

Spin- Outs - Case Studies From The Pharmaceutical Industry,

Research and Technology Management, pp . 32 - 42.

11. Witty, Andrew (Jan 2011): New Strategies for Innovation in

Global Health - A Pharmaceutical Industry Perspective, Vol. 30,

No. 1, Health Affairs, pp. 118 -126.

12. Ahn , Mark J ; M eeks, Michael ; Davenport, Sally ; Bednarek,

Rebecca (2 0 1 0 ): Exploring Technology Agglomeration Patterns

for Multinational Pharmaceutical and Biotechnology Firms ,

Journal of Commercial Biotechnology, V ol. ,16, pp . 17 - 32 .

13. M ehra, Kavita ; Joshi, Kirti (August 2010): The Enabling Role

of the Public Sector in Innovation: A Case Study of Drug

Development in India, Innovation: Management, Policy &

Practice ,Vol. 12, Issue 2, pp . 227-237.

14. Pisoni, Alessia ; Onetti, Alberto ; Fratocchi, Luciano ; Talaia,

Marco (2 0 1 0 ): Managing R & D Activities in the Italian Biotech

Industry- A Comparison of Investments from MNCs and

Domestic Firms , The IUP Journal of Knowledge Management,

Vol. V III,N o.3, p p .3 9 -5 9 .

15. Keyhani, Salomeh ; Wang, Steven ; Hebert, P aul; Carpenter,

Daniel; Anderson, Gerard ( June 2010 ) : US Pharmaceutical

Innovation in an International Context, American Journal of

Public Health, Vol. 100, No. 6 , pp . 1075 -1085.

16. YUE , Fei- f e i; YUE ,Ying-ming (2 0 1 0 ): Study of Comparative

Advantages of Chinese and Indian Pharmaceutical Industries

Under Globalization, Management Science and Engineering, Vol.

4, No. 4, pp. 82 - 86.

17. You-Sang, KOH ( April 2010): Expanding Applications and Uses

of Biotechnology, ( Samsung Economic Research Institute) SERI

Quarterly ,pp . 40 - 48.

18. Kaufman , Michele B. ( December 2010): Management With

Specialty Pharmaceuticals Imminent for Various Conditions ,

www.formularyjournal.com , Vol. 45 , p p . 359 .

19. Kaufman , Michele B. ( December 2010): The Non - Specialty

Pharmaceutical Pipeline- What’s On the Horizon? ,

www.formularyjournal.com , Vol. 45, pp. 360.

20. Menzel, Vanessa ; Smagin , Jan ; David, Felix (2010 ): Can

Companies Profit from Greener Manufacturing? , Measuring

Business Excellence, Vol. 14, No. 2, pp. 22-31.

21. Wang ,Yow-Ming C ; Chow, Andrew T. (2 0 1 0 ): Development of

Biosimilars — Pharmacokinetic and Pharmacodynamic

Considerations , Journal of Biopharmaceutical Statistics, V o l. 20,

pp. 46-61.

22. Eriksson, Paivi; Rajamaki, Heidi (2010): Biotechnology

Marketing: Insider and Outsider Views, Journal of Commercial

Biotechnology Vol. 16, p p . 98 -108.

23. Doc. dr. sc. Bertoncelj, Andrej (2010) - Importance of Marketing

Management in the World Pharmaceutical Industry, TRZISTE ,

pp.79 - 93 Vol. XX (2008), br. 1, str. 79 - 93.

24. Quintana-garcia, Cristina; Benavides-Velasco, Carlos A. (June

2010): Accessing Technological Knowledge Through R&D

Alliances -Consequences for Radical and Incremental Innovation,

Strategy, Organization and Technology Management, pp. 1 - 37.

25. Aalbers, Rick (2010): The Role of Contracts and Trust in R&D

Alliances in the Dutch Biotech Sector, Volume 12, Issue 3,

December 2010 Innovation: Management, Policy & Practice pp.

311-329.

26. Kim, Changsu; Park, Jong-Hun (2010): The Global Research and

Development Network and its Effect on Innovation, Journal of

International Marketing, Vol. 18, No. 4, pp. 43-57.

27. Dubey, Jayashree ; Dubey, Rajesh (2010): Pharmaceutical

Innovation and Generic Challenge - Recent Trends and Causal

Factors , International Journal of Pharmaceutical and

Healthcare Marketing, Vol. 4, No. 2, pp. 175-190.

28. Ahn , Mark J ; Y ork, Anne S ; Rizova , Polly ( 2010):

Pathways to Biomedical Tipping Points: Vertical, Horizontal or

Other ?, Journal of Commercial Biotechnology, Vol .16, pp . 224 -

238.

29. Nunnally, Brian K ; McConnell, John S. ( Summer 2010): Six

Sigma in the Pharmaceutical Industry, Understanding, Reducing,

and Controlling Variation in Pharmaceuticals and Biologies, Vol.

14, N o . 3 , Open Jounal, pp. 9.

30. Maine, Elicia M.; Shapiro, Daniel M.; Vining, Aidan R. (2010):

The Role of Clustering in the Growth of New Technology-based

Firms, Small Business Economics ,Vol.34, pp.127-146.

31. Williams, David R ; Pouder, Richard W (2 0 1 0 ): R & D

Spending and Sources of Funding of Private US

Biopharmaceutical Firms Seeking to go Public, Journal of

Commercial Biotechnology ,Vol .1 6 ,2 8 4 -2 9 2 .

32. Menzel, Max-Peter ; Fornahl, Dirk ( July 2010): Cluster Life

Cycles—Dimensions and Rationales of Cluster Evolution,

Industrial and Corporate Change, Volume 19, Number 1, pp. 205-

238.

33. Wennberg, K arl; Lindqvist, GOran (2 0 1 0 ): The Effect of

Clusters on the Survival and Performance of New Firm s, Small

Business Economics, V ol. 34, pp. 221 - 241.

34. Allarakhia . D, Minna ; Kilgour, D. Marc ; Fuller, J. David(2010)

Modelling the Incentive to Participate in Open Source

Biopharmaceutical Innovation, R & D Management, V o l. 40,

No . 1, pp. 50 -66.

35. Moensted , Mette (April 2010): Networking and

Entrepreneurship in Small High-Tech European Firms - An

Empirical Study, International Journal of Management, Vol. 27 ,

No. 1, pp. 1 6 -3 1 .

36. Paruchuri, Srikanth ( January - February 2010):

Intraorganizational Networks, Interorganizational Networks ,

and the Impact of Central Inventors - A Longitudinal Study of

Pharmaceutical Firms, Organization Science, V o l. 21 , No . 1 , pp.

6 3 - 8 0 .

37. Sowlay, Mohan; Lloyd, Scott (January 2010): The Current M & A

Environment and its Strategic Implications for Emerging

Biotherapeutics Companies, Special Report - Journal of

Commercial Biotechnology, pp. 10 -1 4 .

38. Mayhew, Stephen (2010): Practical Approaches to Early Stage

Life Sciences Technology Valuations, Journal of Commercial

Biotechnology, Vol.16, pp. 120 -134 .

39. Hemphill, Thomas A. (January 2010): Pharmaceutical Patent

Expropriation and Technology Strategy: Strategic Options to

Compulsory Licensing, Technology Analysis & Strategic

Management, Vol. 22, No. 1, pp. 19 - 41.

40. Miller, J.; Johnson, A. (2010): Managing Disruptions in

Pharmaceutical Supply Chain Networks, Industrial Engineering,

pp. 1 - 6 .

41. Sowlay, Mohan; Lloyd, Scott (March 2010): Pharmaceutical

Industry - Transformation, Special Report - Journal of

Commercial Biotechnology, pp. 1 - 3 .

42. Sowlay, Mohan; Lloyd, Scott ( June 2010): Biotech in Healthcare

Business, Special Report - Journal of Commercial Biotechnology,

pp. 1 - 2 .

43. Rothaermel, Frank.T ; Hess , Andrew . M ( 2010 ) : Innovation

Strategies in Biotechnology, Special Report - Journal of Advances

in Management Research , pp. 4 - 5

44. Sowlay, Mohan; Lloyd, Scott (December 2010): M & A for

Emerging Biotherapeutics Companies, Special Report - Journal of

Commercial Biotechnology, pp. 1.

45. Khemka , Meenakshi; Gautam, Vinayshil (2010): Innovation in

the Pharmaceutical Industry - Study of Select Parameters ,

Journal of Advances in Management Research ,Vol. 7, No. 1,2011,

pp. 127 -138 .

46. Al-Laham , Andreas ; Amburgey, Terry L. (2010): Who Makes

You Central? Analyzing the Influence of International Alliance

Experience on Network Centrality of Start-up Firms,

Management, International Review V ol. 50, pp. 297-323.

47. Juan Enriquez (McKinsey Quarterly - February 23,2009): What

Matters - How Biotech Will Reshape the Global Economy, pp. 1 -

3.

48. Haseltine , William . A. ( McKinsey Quarterly - February 23,

2009): What Matters - Transforming the Material World , pp. 1-

4.

49. Stremersch , Stefan ; Van Dyck, Walter ( July 2009): Marketing

of the Life Sciences - A New Framework and Research Agenda

for a Nascent Field, Journal of Marketing V ol. 73 , pp. 4 - 30.

50. D aar, Abdallah ( McKinsey Quarterly - February 23,2009 ) :

What Matters - Big Changes, Coming Soon , pp.l.

51. Frosst, Phyllis. D. (McKinsey Quarterly - February 23,2009):

What Matters - Prognosis for Personalized Medicine, pp. 1 - 3 .

52. Woehr, Torsten ; New, Marc (2 0 0 9 ): Custom Manufacturing,

Differentiating Strategies and Success Factors for the Future,

Industry and Business , pp. 1- 4.

53. Glasberg, Glenn (2009): Japan’s Global Pharma / Biotech

Impact, The Open Business Journal - Special Report - 2009, pp. 1

54. Ahn , M ark. J .; Meeks, Michael (January 2008): Building a

Conducive Environment for Life Science - Based

Entrepreneurship and Industry Clusters , Journal of Commercial

Biotechnology, Vol.14, No.l, pp.20 - 30.

55. Ibata - Arens , Kathryn (July 2008): Comparing National

Innovation Systems in Japan and the United States - Push, Pull,

Drag, Jump Factors in the Development of New Technology, Asia

Pacific Business Review, Vol. 14, No. 3 , pp. 315-338.

56. Birch, Kean (January 2008): The Importance of Clustering in the

Biotechnology Sector, Special Report - Economic Geography,

pp. 1 -4 .

57. Birch, Kean (January 2008): An Alternative Approach to the

Cluster Theory -from the Perspective of the Biotechnology

Industry in UK, Special Report-Economic Geography, pp. 20 - 25.

58. Glick, J. Leslie ( April 2008 ) : Biotechnology Business Models

Work - Evidence from the Pharmaceutical Market Place, Journal

of Commercial Biotechnology, Vol.14, No. 2, pp.106 -1 1 7 .

59. Gottinger, Hans-Werner; Umali, Celia L. (2 0 0 8 ): Strategic

Alliances in Global Biotech Pharma Industries , The Open

Business Journal, Vol. 1, pp. 10-24.

60. Kapeleris, John; Hine, Damian (January 8,2008): Innovation and

Entrepreneurship in Biotechnology, The Open Business Journal -

Special Report, pp. 1.

61. Chiaroni, Davide ; Chiesa , Vittorio ; Frattini, Federico (2 0 0 8 ):

Patterns of Collaboration along the Bio - Pharmaceutical

Innovation Process, Journal of Business Chemistry, Vol .5, No.l,

pp. 7 - 2 2 .

62. Berthon , Pierre ; Pitt, Leyland ; N el, Deon ; Salehi - Sangani,

Esm ail; Engstrom, Anne ( July 2008): The Biotechnology and

Marketing Interface - Functional Integration Using Mechanistic

and Holographic Response to Environmental Turbulence, Journal

of Commercial Biotechnology, Vol.14, No.3, pp.213 - 224.

63. Rajamaki, Heidi ( July 2008): Anticipating and Managing the

Challenges of Biotechnology Marketing, Journal of Commercial

Biotechnology , Vol.14, No.3, pp . 225-231 .

64. Liang, Shing - Ko ; Jiang, Jyun - Lin ; L a i, Chia - Te (March

2008): Effects of Integrative Strategies on the Production

Efficiency of Biotechnology Firms - A Data Development Analysis

, International Journal of Management, Vol.25, No.l, pp.140 -

148

65. Rao, Raghunath Singh; Chandy, Rajesh. K; Prabhu , Jaideep . C

(July 2008): The Fruits of Legitimacy - Why Some New Ventures

Gain More from Innovations Than Others, Journal of Marketing

, Vol. 7 2 ,pp. 5 8 -7 5 .

66. Vanderbyl, Sandra ; Kobelak, Sherry ( February 2007 ) : Critical

Success Actors for Biotechnology Industry in Canada, Journal of

Commercial Biotechnology ,Vol .13, No. 2, pp.68 - 77.

67. Brannback, Malin ; Carsrud , Alan ; Renko, Maija (March

2007): Exploring the Born Global Concept in the Biotechnology

Context, Journal of Enterprising Culture, Vol. 15, No.l, pp.79 -

100.

68. Kind, Sonja; Knyphausen - Aufsef), Dodo Zu (April 2007):

Business Development - What is “Business Development?” The

Case of Biotechnology, SBR 59, pp.176 -199 .

69. Frahm, Jennifer; Ireland, David .C ; Hine, Damian (May 2007):

Constructing a Processual Model of Communication in New

Product Development from a Multiple Case Study of Biotech

SMEs, Journal of Commercial Biotechnology ,V ol. 13, No. 3, pp.

151-161.

70. Cader, Yoosuf (May 2007): Knowledge Management and

Knowledge - Based Marketing, Journal of Business chemistry,

Vol. 4, Issue 2, pp. 46 - 58.

71. Coman , A ; Ronen , B ( February 2007 ) : Managing Strategic

and Tactical Constraints in the Hi - Tech Industry, International

Journal of Production Research, Vol. 45 , N o . 4 , pp. 779 - 788.

72. Fontes, Margarida (May 2007): Technological Entrepreneurship

and Capability Building in Biotechnology, Special Report -

Technology Analysis and Strategic Management, pp.l -15.

73. Wolson, Rosemary. A (2007): The Role of Technology Transfer

Offices in Building the South African Biotechnology Sector - An

Assessment of Policies , Practices, and Impact, Journal of

Technology Transfer, Vol.32, pp.343 - 365.

74. ThorsteinsdOttir, Halla (September 2007) : The Role of the

Health System in Health Biotechnology in Developing Countries ,

Technology Analysis and Strategic Management, Vol.19, No. 5,

pp.659 - 675.

75. Mittra , James (May 2007): Life Science Innovation and the

Restructuring of the Pharmaceutical Industry - Merger,

Acquisitions and Strategic Alliance Behavior of Large Firms,

Technology Analysis and Strategic Management, Vol.19, No.3, pp.

279-301 .

76. Kleyn, Dominique; Kitney, Richard; Atun, Rifat. A (June 2007):

Partnership and Innovation in the Life Sciences , International

Journal of Innovation Management, Vol. 11, No.2, pp.323 - 347.

77. Lane, Christel; Probert, Jocelyn (February 2007) : The External

Sourcing of Technological Knowledge by US Pharmaceutical

Companies - Strategic Goals and Inter - Organizational

Relationships , Industry and Innovation ,V ol. 14, N o .l , pp. 5 -

25.

78. Sen , Sharmistha Bagchi (July 2007): Strategic Considerations

for Innovation and Commercialization in the US Biotechnology

Sector, European Planning Studies, Vol.l5,No.6, pp.753 - 766.

79. Couillard , Denis (July / August 2007): Why Creating a Learning

Organization Leads the High Tech Firm to Succeed, Ivey Business

Journal -London, pp.l - 7.

80. TO dt, Oliver ; Gutierrez - Gracia, Antonio ; Fernandez de

Lucio , Ignacio ; Castro - Martinez, Elena (2007): The Regional

Dimension of Innovation and the Globalization of Science -The

Case of Biotechnology in a Peripheral Region of the European

Union , R & D Management, V ol. 37, No.l, pp.65 - 74.

81. Rothman , Harry ; K raft, Alison (January 2006): Downstream

and into Deep Biology- Evolving Business Models in “ Top Tier “

Genomics Companies, Journal of Commercial Biotechnology,

Vol.12, No.2, pp. 86 - 98

82. W olff, M.F. (January - February - 2006) : Views and News of

the Current Research - Technology Management Scene -

Perspectives - South East Asia Drives for Biotech Supremacy,

Research and Technology Management, pp . 2 - 4.

83. Traore, Namatie (March 2006): Networks and Rapid

Technological Change - Novel Evidence from the Canadian

Biotechnology Industry ,Industry and Innovation , Vol .13, No.l,

pp. 41 - 68.

84. Okamura, Koichiro; Vonortas, Nicholas.S (December 2006):

Alliance and Knowledge Networks, Technology Analysis and

Strategic Management, Vol. 18, No . 5 , pp. 535 - 560.

85. Baskaran , Angathevar; Pancholi, Jatin ; Ghaffari, Firoozeh

( Summer 2006): A Period Study of Short - Term Performance

Pressures : Case of the British Biotechnology Industry, The

Business Review - Cambridge, Vol. 5,No.2, pp.327 - 332.

86. Churchill, Clare. A . C .; Belsey, Mark . J (April 2006):

Autoimmune and Inflammatory Disorder Biologicals Will Power

Biotech Market Growth Through to 2010, Journal of Commercial

Biotechnology, Vol. 12, N o . 3, pp. 237 - 241.

87. Quezada , Fernando ( April 2006): Commercial Biotechnology in

Latin America - Current Opportunities and Challenges, Journal

of Commercial Biotechnology, Vol.12, No.3, pp.192 -199 .

88. Nosella, Anna ; Petroni, Giorgio ; Verbano , Chiara ( May 2006)

: How Do Italian Biotechnology Start - Ups Survive ?,Journal of

Business Chemistry, Vol.3, Issue No.2, pp.7 -1 4 .

89. Ramirez, Paulina ( May 2006 ) : The Globalization of Research

in the Pharmaceutical Industry - A Case of Uneven Development,

Technology Analysis and Strategic Management, Vol.18, No.2,

pp.143 -1 6 7 .

90. Maurer, Indre ; Ebers, M ark; ( June 2006): Dynamics of Social

Capital and their Performance Implications- Lessons from

Biotechnology Start - U ps, Administrative Science Quarterly (

A SQ ) ,VoL51, pp. 262 - 292.

91. Pijpers , Fleur; Belsey, Mark . J . ( July 2006 ) : Cancer

Remains the Dominant Disease Target for Biotech Through to

2010 , Journal of Commercial Biotechnology, Vol. 12, No.4, pp .

294-298 .

92. Johnston , Kate ; Henry, Colette ; Gillespie, Simon ( August 8 ,

2006): Encouraging R & D in Ireland’s Biotechnology

Enterprises, The Irish Journal of Management, Vol .9, pp.207 -

228.

93. Sedgley , Mike ( September 2006): Pharmaceutical and

Government Policy - The State Giveth and the State Taketh Away

- Supporting the Research Based Pharmaceutical Industry in

Europe and the UK, Institute of Economic Affairs (IEA), pp. 39 -

47.

94. Pisano , Gary . P. (October 2006): Can Science Be a Business? -

Lessons from Biotech, Harvard Business Review, pp. 114 -125 .

95. W ong, Joseph ( October 2006): Technovation in Taiwan :

Implications for Industrial Governance, International Journal of

Policy, Administration , and Institutions,Vol.19, No.4, pp . 651 -

672.

96. Mytelka, Lynn. K. ( December 2006) :Pathways and Policies to (

B io) Pharmaceutical Innovation System in Developing Countries

,Industry and Innovation, Vol.13, No.4, pp.415 - 435.

97. Bower, Jane. D ; Sulej, Julian ( December 2006): Social and

Intellectual Capital Formation in Leading Indian Pharmaceutical

Companies, International Journal of Innovation Management,

Vol.10, No.4, pp. 407-423.

98. Hendry, Chris ; Brown, James (2 0 0 6 ): Organizational

Networking in UK Biotechnology Clusters , British Journal of

Management, Vol.17, pp.55 - 73.

99. Fetterhoff, Terry. J .; Voelkel, Dirk ( 2006): Managing Open

Innovation in Biotechnology, Research and Technology

Management, pp. 14 - 18.

100. Hagedoorn , John ; Roijakkers, Nadine; Kranenburg, Hans

Van ( 2006): Inter - Firm R & D Networks - The Importance

of Strategic Network Capabilities for High-Tech Partnership

Formation, British Journal of Management, Vol. 17 , p p . 39 - 53.

101. Khilji, Shaista. E .; Mroczkowski, Tomasz ; Bernstein, Boaz (

2006): From Invention To Innovation - Toward Developing an

Integrated Innovation Model for Biotech Firms , The Journal of

Product Innovation Management ( J Prod Innov Manag) , Vol.

23 ,pp. 528 - 540.

102. Englande, A. J . ; J in , Guang (2 0 0 6 ): Application of

Biotechnology in Waste Management for Sustainable

Development - An Overview, International Journal of

Management and Environmental Quality, Vol.17, No.4, pp. 467 -

477.

103. Burow, Scott. A.; Berghammer, Joseph . J. ( August 2006):

Patent Protection in the Biotechnology Industry - A Unique

Approach to Obtaining Fast Patent Rights,Intellectual Property

and Technology Law Journal, V ol. 18, No. 8, pp. 18 - 20.

104. Attridge , Jim ( September 2006): Pharmaceuticals and

Government Policy - Equity of Access to Innovative Medicines -

Mission Impossible ?, Institute of Economic Affairs ( IEA ) ,pp.l7

-23

105. Lim , L isa. P . L .; Garnsey, Elizabeth ; Gregory, Mike (

2006): Product and Process Innovation in Biopharmaceuticals -

A New Perspective on Development, R & D Management, Vol .36,

No.l, pp . 27 -3 6 .

106. Vazquez, Emma Gutierrez de Mesa ; Martin, Juan Angel

Jimenez ; Mascarenas , Juan ( April 2006): Strategic Alliances

as a Mechanism for Wealth Creation in the Biopharmaceutical

Industry - an Empirical Analysis of the Spanish C ase, Journal

of Commercial Biotechnology, V ol. 12 , No. 3 , pp .229 - 236.

107. Gollin, Michael; Jack, Eva ; Chase, Terry; Soriano, Jesus;

Smith, Robert ( April 2006): Winning the Game - Public Funds

for Biotech Companies, Journal of Commercial Biotechnology,

Vol. 12, No.3, pp. 220-228.

108. Pavlou , Alex ; Belsey , Mark ( January 2005) : Key Financial

Trends that Shape Biotechnology Business Growth , Journal of

Commercial Biotechnology, V ol. 11, No. 2 , pp. 171 -1 7 5 .

109. Joshi, Sanjaya.N (June 2005): Creating a Biotechnology Hub -

Lessons from the BioForest, IIMB Management Review, pp. 50 -

58.

110. Blau, John (November - December 2005): German Biotech -

Coming Back, Research and Technology Management, pp. 4- 5 .

111. Kowalski, Thomas . T ; Fekete, Pamela ; Yvon, Anne - Marie.

C (April 2005): The Quest for Generic Biotechnology

Pharmaceuticals in the USA, Journal of Commercial

Biotechnology, Vol .11, No.3, pp. 271 -274 .

112. Bower, Jane. D (June 2005): From the “Rhetoric of Hope” to

the “Patient - Active Paradigm” - Strategic Positioning of

Pharmaceutical and Biotechnology Companies, Technology

Analysis and Strategic Management, Vol. 17, No. 2, pp . 183 -

204.

113. Ghadar, Fariborz ; Spindler, Heather (March - April 2005)

Global Tectonics - Part I - The Growth of Biotechnology,

Industrial Management, p p . 19 - 23

114. Schweizer, Lars (2 0 0 5 ): Organizational Integration of

Acquired Biotechnology Companies into Pharmaceutical

Companies - The Need for a Hybrid Approach, Academy of

Management Journal ,Vol.48, No.6, pp .1051-1074.

115. Laroia , Gaurav ; Krishnan, Shiv ( September - October -

2005 ) : Managing Drug Discovery Alliances for Success -

Applying the Lessons Learned from Aventis‘s Alliance

Experience Could Improve the Productivity of Such Alliances,

Research and Technology Management, pp. 42 - 50.

116. Salman, Nader; Saives , Anne - Laure (2 0 0 5 ): Indirect

Networks - An Intangible Resource for Biotechnology Innovation,

R & D Management, V ol. 35, No.2, pp. 203 - 305.

117. Baker, Ann; Gill, Jasween (October 2005): Rethinking

Innovation in Pharmaceutical R & D , Journal of Commercial

Biotechnology, Vol. 12, No. 1, pp. 45 - 49.

118. Termeer, Henri. A (July 25,2005): The Alchemy of

Biotechnology - Third Edition, Boston Globe, Boston,

Massachusetts, pp. 267 - 268.

119. Gertler, M. S; Levitte, Y. M. (December 2005): Local Nodes in

Global Networks; The Geography of Knowledge Flows in

Biotechnology Innovation, Industry and Innovation, Vol. 12, No. 4,

pp.487 - 507.

120. Nicholson , Sean ; M. Danzon, Patricia ; McCullough, Jeffery (

July 2005 ) : Biotech - Pharmaceutical Alliances as a Signal of

Asset and Firm Quality, The Journal of Business, V o l. 78, No. 4,

pp. 1433 -1464.

121. Fontes, Margarida (September 2005): Distant Networking -

The Knowledge Acquisition Strategies of “Out - Cluster

“Biotechnology Firms, Special Report - European Planning

Studies, pp. 1-21

122. Fontes , Margarida ( December 2005): Building Capabilities

in Biotechnology, Special Report - European Planning Studies, pp.

1- 11.

123. Filho, Lelio Felows ; Maria dos Santos , D alci; Coelho, Gilda

M assari; Santos , Marcio de Miranda ( September 2005): Future

Studies in Brazil: Centro de Gestao e Estudos Estrategicos

(CGEE) Approach for Biotechnology and Nanotechnology,

Journal of Business Chemistry, V ol. 2 , Issue 3 , pp.126 -1 3 7

124. Williams, Alan (April 2005): Corporate Development in

Biotech in 2005, Journal of Commercial Biotechnology, Vol. 11,

No. 3, pp. 239-248 .

125. Parayil, Govindan (Winter 2005): From “Silicon Island “ to “

Biopolis of Asia “ - Innovation Policy and Shifting Competitive

Strategy in Singapore , California Management Review ( CM R) ,

V ol. 47, No. 2, pp. 5 0 - 7

126. Anonymous (March - April 2005): EU Scoreboard Reveals

Need for Industrial R & D Champs- EU Industrial R & D

Investment Scoreboard, Research and Technology Management,

pp. 5 - 8 .

127. Lynskey, Michael. J. (July 2005): Moving Beyond Metaphors -

University - Industry Collaboration in Biotechnology, Journal of

Commercial Biotechnology, V ol. 11, No. 4, pp. 301 -304 .

128. Piachaud , Bianca ( May - June 2005): Outsourcing

Technology,Research and Technology Management, pp . 40 - 46.

129. Garcia; Quintana ; Velasco , Benavides ( November 15,2005)

: Agglomeration Economies and Vertical Alliances : The Route to

Product Innovation in Biotechnology Firms, International

Journal of Production Research, V o l. 43, No. 22, pp. 4853-4873.

130. Sell, Christopher (January 28,2005): Applied Technologies for

Production Engineers; Production Engineering, Industrial Biotech

pp. 31-33.

131. Howell, Julian ( July 2004): The Why and How of US

Market Entry : A Qualitative Study of Non - US Pharmaceutical

Companies, International Journal of Medical Marketing, V ol. 4,

No. 3, pp. 235-250 .

132. Finegold , David ; W ong, Poh - Kam Wong ; Cheah , Tsui -

Chern ( October 2004): Adapting a Foreign Direct Investment

Strategy to the Knowledge Economy - The Case of Singapore’s

Emerging Biotechnology Cluster, European Planning Studies ,

V ol. 12 ,No. 7 ,p p .921-941.

133. Philip Cooke (May 2004) :Life Sciences Clusters and Regional

Science Policy, Urban Studies, Vol. 41, Nos. 5 & 6 , pp. 1113 -1131

134. Lawton Smith, Helen (October 2004): The Biotechnology

Industry in Oxfordshire - Enterprises and Innovation, European

Planning Studies, Vol. 12, No. 7, pp. 985 -1001.

135. Kean, Marcia. A(May 2004):Biotech and the Pharmaceutical

Industry - Back to the Future, The Observer , No . 243, pp. 21 -

22.

136. Kak, Anjana (2004): Strategic Management, Core

Competence and Flexibility - Learning Issues for Select

Pharmaceutical Organizations, Global Journal of Flexible Systems

Management, Vol. 5, No. 4, pp 1-15.

137. Asia Pacific Biotech News ( APBN 2004): How Biotechnology

Can Improve Global Health - Global Development ,Vol.8 , No.6

pp. 3 40 -342

138. P. L .Lim, Lisa; J. Gregory, Michael (June 2004): Singapore’s

Biomedical Science Sector Development Strategy; Is it

Sustainable? , Journal of Commercial Biotechnology; Vol. 10, No.

4, pp.352 - 362.

139. Anonymous (October 2004): Biotechnology Industry Finds

Fertile Ground in The Netherlands, Biopharm International, V ol.

17, No. 10, pp. 62 - 68.

140. Mamidi, Pavan ( June 2004 ) : Biotechnology and Business,

IIMB Management Review, pp. 49 - 62.

141. Anonymous (September - October 2004): Tech Talk -R & D ,

Research and Technology Management, pp. 5 - 6 .

142. Thumm, Nikolaus (December 2004): Strategic Patenting in

Biotechnology, Technology Analysis and Strategic Management,

V ol. 16, No. 4 ,5 2 9 -5 3 8 .

143. Rzakhanou , Zaur (December 2004): Innovation , Product

Development, and Market Value : Evidence from the

Biotechnology Industry, Economic Innovation New Technology,

V ol. 13,No. 8, pp. 747-760.

144. Hennessey, Raymond (January 8 ,2004): Deal and deal

makers - IPO‘s for Biotech Face Skepticism After a Rough 2003 ,

The Wall Street Journal - Eastern Edition, - New York -NY,

p p .1 -2

145. LOffler, Alicia (2004): The Evolving Role of Marketing in

Biotechnology, Biotech Ventures, pp. 1- 4.

146. L6ffler, Alicia (2004): Optimizing the Marketing Function,

The Open Business Journal- Special Reports -2004, pp. 11-15.

147. Han, Dr. Yongliang “Staanley “(September 2004): Is

Technology Pre - emption a Motive for R & D Alliances?

Evidence from the Biotechnology Industry, Journal of American

Academy of Business - Cambridge, V ol. 5, Nos. 1 & 2, pp.215 -

219.

148. Prahalad , C.K ; Ramaswamy , Venkatram ( 2004 ) : The

Future of Competition - Co - Creating Unique Value with

Customers , HBR School Press , Boston , MA.

149. Chiesa, Vittorio; Toletti, Giovanni (March 2004): Network of

Collaborations for Innovation- The Case of Biotechnology,

Technology Analysis and Strategic Management, Vol. 16, No. 1 ,

pp. 73 - 96.

150. Acemoglu, Daron ; Linn, Joshua ( August 2004): Market Size

in Innovation - Theory and Evidence from the Pharmaceutical

Industry, The Quarterly Journal of Economics ,pp. 1049 -1090.

151. Lehrer, M ark; Asakawa, Kazuhiro (Spring 2004): Pushing

Scientists into the Market Place : Promoting Science

Entrepreneurship , CM R, V ol. 46, No. 3, pp. 55 - 76.

152. Asia Pacific Biotech News (2 0 0 4 ): Singapore’s Conducive

Biomedical Sciences Environment, V ol. 8 , No . 5 , pp. 272 - 273.

153. Leibovitz, Joseph (May 2004): Embryonic Knowledge - based

Clusters and Cities: The Case of Biotechnology in Scotland, Urban

Studies, Vol. 41 , Nos. 5 & 6, pp. 1133 -1155.

154. M uller, Christian ; Fujiwara, Takao ; Herstatt, Cornelius

( 2004): Sources of Bio- entrepreneurship - The Cases of

Germany and Japan , Journal of Small Business Management,

V ol. 42, No. 1, pp.93 - 101.

155. De Rond, M; Bouchikhi, Hamid (2004): Strategic Alliances,

Organization Science, Vol. 15, No. 1, pp. 68.

156. McCarthy, Robert. C (March - April 2003): Linking

Technology Change to Business Needs, Research and Technology

Management, pp. 47 - 52

157. Howard, Nigel (October 28 ,2003): Exploring Strategy

Through Outsourcing in the Biotech Industry, The Open Business

Journal Special Reports - 2003, pp. 1.

158. Varaiya , N ikhil. P .; Evans , Anne. G . ( Fall 2003):

Assessment of a Biotechnology Market Opportunity,

Entrepreneurship Theory and Practice,pp. 87 - 105.

159. K, Balaji ( 2003 ) : Competitive Positioning Strategies for

Australian Biotechnology Companies, Global Biotechnology

Market Overview and Opportunity Analysis, 2003, pp.4 -7.

160. Cooper, John (March 2003): The Biotech Boom Builders,

CMA Management, Vol. 77, No. 1, pp. 24 -29.

161. Asia Pacific Biotech News (APBN 2003): Vol .7, No.10, pp.512.

162. Asia Pacific Biotech News ( APBN 2003): Vol .7 , No.15 ,

pp.913.

163. Frost and Sullivan ( APBN 2003) : Special report - Asia

Pacific Biotech News APBN (2003 ) , pp.l

164. Anonymous (December 2003): Bio- information -

Biotechnology R & D , The Observer, No. 240 -241, pp.

165. Anonymous (December 2003): Bitter Pill - Higher

Pharmaceutical Spending, The Observer, No. 240 -241, pp. 85.

166. Quere, Michel ( September 2003): Knowledge Dynamics -

Biotechnology ‘s Incursion into the Pharmaceutical Industry,

Special Report - Industry and Innovation , pp.l - 25.

167. Quere, Michel (April 2003): Current Development of Bio -

Informatics, Special Report - Industry and Innovation, pp. 1-15.

168. Cooke, Philip ( October 2003): The Evolution of

Biotechnology in Three Continents : Schumpeterian or

Penrosian, European Planning Studies, V ol. 11, No. 7 , p p . 757 -

763.

169. Kermani, Faiz ; Bonacossa, Pietra ( December - 2003):

Current and Future Prospects for the Global Biotechnology

Industry, Journal of Commercial Biotechnology ,Vol.l0, No.2 ,

pp.154 -164 .

170. Pavlou, Alex. K. (January 2003): Biotechnology Industry -

Insights from Europe, Journal of Commercial Biotechnology,

Special Report - pp. 1-11.

171. Pavlou, Alex. P. (December 2003): Leading Biotechnology

Players 2002: 2008 - Key Products - Indications and Technologies,

Journal of Commercial Biotechnology; Vol. 10, No. 2, pp. 167 -

176.

172. Jen Fr0slev Christensen ( September 2003 ) : The Industrial

Dynamics of Biotechnology - New Insights and New Agendas —

Introduction , Industry and Innovation , Vol.10, No.3, pp. 223 -

230.

173. Frost & Sullivan (APBN 2003): Asia Pacific Biotech news,

Global Biotechnology Market Overview, Vol. 7, No. 12, pp.704 -

707.

174. K ato, Makino ; Macer, Darryl ( January 2003): How

Biotechnology Companies Respond to Bioethical Issues, Journal

of Commercial Biotechnology, V ol. 19, No. 2, pp. 153 -162 .

175. Mcgarvey, Robert ( May 2003 ) : Biotech Advances -

Transforming Our Lives With New Drugs , Better Crops, Even

Personalized Medicines, HBR Publication Corporation, p p . 51 -

53

176. Newton, Alastair (November 2003): Europe4s Biotechnology

Hub - The UK, Biopharm International, Vol. 16, No. 11, pp. 52 -

58.

177. Carbone , June ( July 2003 ): Ethics , Patents and the

Sustainability of the Biotech Business M odel, International

Review of Law Computers and Technology, V o l. 17, No. 2, pp.

203-218 .

178. Lloyd, Wayne (January 2003): A New Era of Networking,

Journal of Commercial Biotechnology, Vol. 9, No. 2, pp. 97 - 98.

179. Weinstein, Olivier; Orsi, Fabienne; Coriat, Benjamin

(September 2003): Does Biotech Reflect a New Science - based

Innovation Regime? , Industry and Innovation, Vol. 10, No. 3, pp.

231-253.

180. Pavlou, A lex. K . ( June 2003) .'Trends in Biotherapeutics,

Journal of Commercial Biotechnology , Vol 9, No.4, pp.358 - 363.

181. Baker, Ann ( June 2003 ) : Opinion Piece - Biotechnology -

Growth - Innovation Paradox and the New Model for Success ,

Journal of Commercial Biotechnology, V ol. 9, No . 4, pp. 286 -

288.

182. Sorescu, Alina. B; Chandy, Rajesh. K; Prabhu, Jaideep. C

(October 2003): Sources and Financial Consequences of Radical

Innovation - Insights from Pharmaceuticals, Journal of

Marketing, Vol. 67, pp. 82 - 102

183. Anonymous ( 2003): New Drug Development - Increasing

Costs , Mckinsey Quarterly , pp.4.

184. Asia Pacific Biotech News ( APBN 2003): General

Information & Statistics - India - Southern India Cities Poised for

Fast Biotech Growth, pp.53.

185. Anonymous ( May 24 ,2 0 0 3 ): The Insider - Biobusiness

Trends - Europe’s Biotech Woes ,The New Scientist - London ,Vol

. 178 , Issue 2396 , pp . 61 - 62

186. Grupp, Robert. W ; Gaines - Ross , Leslie ( September 2002)

: Reputation Management in the Biotechnology Industry ,

Journal of Commercial Biotechnology, V o l. 9, No.l, pp. 17 - 26.

187. Zollo , Maurizio ; Rever, Jeffery; Singh , Harbir (

November - December 2002): Inter - Organization Routines

and Performance in Strategic Alliances, Organisation Science , Vol

. 13, No. 6, pp. 701 - 713.

188. D ing, Ming ; Eliashberg, Jehoshua ( March 2002):

Structuring the New Product Development ( NPD ) Pipeline,

Management Science, V ol. 48 , No. 3 ,pp. 343 - 363

189. Muller, Christian (2002): Strategic Management - A Tool for

Growth in the Biotechnology Sector, Journal of Commercial

Biotechnology, Vol. 8, No. 3 , pp. 226 - 234.

190. LOffler, Alicia (2002 ) - Trends in Biotechnology -

Implications for the Pharmaceutical Industry, International

Journal of Medical Marketing, V ol. 2 , No. 4 , pp. 345 - 348

191. S, Garrett ( June 2002) : A Framework for Effective Market

Planning and Analysis - Eleven Steps to successful Market

Planning, Pharmaceutical Executive’s Successful Product

Management Supplement, pp . 6-18.

192. Anonymous (2002): Future of Biotechnology - A Mckinsey

and Lehman Brothers Study, Mckinsey Quarterly , pp.l.

193. Fisken , Jane ; Rutherford , Jan ( 2002 ) : Business Models

and Investment Trends in the Biotechnology Industry in Europe,

Journal of Commercial Biotechnology, V o l. 8, No. 3, pp. 191 -

199.

194. Coile, Russell. C ( November / December 2001): Impact of

The “ New Science “ of Genomics - Future Trends , Journal of

Healthcare Management, V ol. 46, No. 6, pp. 365 - 368.

195. Steensma, H. Kevin ; Corley, G. Kevin ( April 2001):

Organizational Context as a Moderator of Theories on Firm

Boundaries for Technology Sourcing, Academy of Management

Journal, V o l. 44, No. 2, pp .271 - 291.

196. Niosi, Jorge; Bas, Thomas. G ( August / September 2001):

The Competencies of Region - Canada’s Clusters in

Biotechnology, Small Business Economics , V o l. 17, Nos. 1 & 2,

pp. 31 - 41.

197. Orsenigo , Luigi ( August / September 2001 ) : The ( Failed)

Development of a Biotechnology Cluster - The Case of Lombardy

, Small Business Economics , V ol. 17 , Nos. 1 & 2 , pp . 77 - 92.

198. Weisenfeld, Ursula ; Reeves , James . C ; Hunck - Meiswinkel,

Astrid ( 2001): Technology Management and Collaboration

Profile - Virtual Companies and Industrial Platforms in the High

- Tech Biotechnology Industries, R & D Management, V ol. 31 ,

No . 1 , pp. 91 -100 .

199. Ostergard , Robert. L ; Tubin, Matthew , J r ; Altman , Jordan

( 2001 ): Stealing from the Past - Globalization , Strategic

Formation and the use of Indigenous Intellectual Property in the

Biotechnology Industry ,Third World Quarterly, Vol. 22, No.4 ,

p p .643 - 656.

200. Feldmann , Maryann . P.; Ronzio , Cynthia. R (2 0 0 1 ):

Closing the Innovative Loop : Moving from the Laboratory to the

Shop Floor in Biotechnology Manufacturing, Entrepreneurship

and Regional Development, V ol. 13, pp. 1-16

201. North, Nigel (March - April 2000): Implementation of

Analytical Technologies in a Pharmaceutical Development

Organization - Looking into the Next Millennium, Journal of

Automated Methods and Management in Chemistry, Vol. 22, No.

2, pp. 41 - 45.

202. Madhok, Anoop ; Osegowitsch , Thomas ( Second Quarter

2000): The International Biotechnology Industry - A Dynamic

Capabilities Perspective, Journal of International Business

Studies , V ol. 31, No. 2, pp. 325 - 335.

203. Mason, James (August 1999): Challenges to the Economic

Evaluation of New Biotechnological Interventions in Healthcare,

Pharmocoeconomics, Vol. 16, No. 2, pp.119 -125 .

204. Himmelsbach, Vawn (June 4,1999): Canada Leads R & D

Efforts in Biotechnology, Computing Canada, Vol.25., No. 22, pp.

2 5 -2 6 .

205. Anonymous (March 1999): How Big is Biotech? , Organization

for Economic Cooperation and Development - The OECD

Observer, March 1999, No. 216, pp. 18 -19.

206. Powell, Walter. W (Spring 1998): Learning from

Collaborations - Knowledge and Networks in the Biotechnology

and Pharmaceutical Industries, California Management Review,

Vol. 40, No. 3, pp. 228 - 240.

207. Dyers , J.H; Singh, H (1998): The Relational View -

Cooperative Strategy and Sources of Inter - organizational

Competitive Advantage, Academy of Management Review, V ol.

23 , No. 4 , pp. 660 - 679.

208. Burgers , Willem . P ; Cromartie, Jane. S ; Davis , Ronnie. J

(1998): Cooperative Competition in Global Industries - The

Strategic Dimension, The International Trade Journal, V o l. X II,

No . 4 , pp . 421 - 445.

209. Pahud de Mortanges , Charles ; Rietbroek, Jan - Willem;

Johns , Cort Maclean (1997): Marketing Pharmaceuticals in

Japan - Background and the Experience of US Firms , European

Journal of Marketing, V ol. 31 , No . 8, pp. 561 -582 .

210. Teecee, D . J ; Pisano . G ; Shuen , A (1997): Dynamic

Capabilities and Strategic Management, Strategic Management

Journal, V ol. 18 , pp . 509 - 533.

211. Oliver, Amalya .L ; Lieberkind , Julia Porter (Winter 1997):

Three Levels of Networking for Sourcing Intellectual Capital in

Biotechnology, International Studies of Management and

Organization, V ol. 27 , No . 4 , p p . 76 -103 .

212. Schmidt, Robert. L (April 1996): A Stochastic Optimization

Model to Improve Production Planning and R & D Resource

Allocation in Biopharmaceutical Production Processes,

Management Science, Vol. 4 2, No. 4, pp. 6 0 3 - 6 1 7.

213. Audretsch , David . B ; Stephan . E ., Paula (June 1996):

Company - Scientist Locational L inks-T he Case of

Biotechnology, The American Economic Review , V ol. 86 , No . 3

, pp . 641 - 652.

214. Burgelman , Robert. A ; Grove, Andrew. S (Winter 1996):

Strategic Dissonance, California Management Review ( CMR

reprint series), V o l . 38, No.2, p p . 3 - 23.

215. M oller, K (1995): Business Marketing - An Interactionand

Networking Perspective, Kluwer Academy Publishers, Boston ,

MA.

216. Yeoh , Poh - Lin (1994): Speed to Global Markets - An

Empirical Prediction of New Product Success in the Ethical

Pharmaceutical Industry, European Journal of Marketing,Vol.

28, No. 11, pp. 2 9 -4 9 .

217. Solt, Michael. E (Summer 1993): SWORD Financing of

Innovation in the Biotechnology Industry, Financial Management,

pp. 173 -187.

218. Barney, Jay (1991): Firm Resources and Sustained

Competitive Advantage, Journal of Management, V o l . 7, No. 1,

pp. 99 -120 .

219. Fildes, Robert. A (Spring 1990): Strategic Challenges in

Commercializing Biotechnology, California Management Review

(CMR), pp. 63 - 72.

220. Arora, Ashish ; Gambardella, Alfonso ( June 1990):

Complementarity and External Linkages - The Strategies of Large

Firms in Biotechnology , The Journal of Industrial Economics,

Volume XXXVIII, No. 4 , p p . 361 - 379.

QUESTIONNAIRE FOR COMPANIES

NAME OF THE COMPANY

ADDRESS:

ANNUAL TURNOVER: INR________ MILLION

NAME OF THE INTERVIEWEE:

DESIGNATION:

1. Does your company have a vision statement?

Yes____No____

2. If yes, what is your company’s vision statement?

3. Does your company have a mission statement?

Yes___No

5 If yes, what is your company’s mission statement?

6 According to you, how does this vision and mission statement help your company achieve its’ objectives?

7 Do you have a defined customer segment(s)?

Yes__________No__________

8 If yes, could you describe the segment(s)?

9 How do you assess user needs?

Market Research__________

Employees’ Feedback____________

Dealers’ / Distributors’ Feedback_________________

Customers’ Feedback_______________

Suggestions for Improvement from Stakeholders, If Any______

10 What is your procedure for generating ideas for improvement / new ideas for product / process?

12 Do you conduct a formal SWOT analysis?

Yes__________No_______ ^

13 Who are your major competitors?

14 Do you have a formal competitor analysis?

Yes__________No__________

15 If yes, how often do you analyze competitors?

16 What opportunities and threats do you perceive for your products?

In One Year___________

In Three Years______________

In Five Years

18 Could you briefly explain your procedure for strategy formulation

19 How do you ensure proper implementation of your strategy?

20 What is the methodology adopted by you fo r:

New Product Development

Design Development

Testing

21 How do you plan and design the manufacturing process?

22 What are your process control techniques / tools :

SPC__________

Six Sigma_________

ISO 9001:2000 QMS_________

Any Other________

23 What is the methodology adopted by you for product / process improvement?

Market Feedback_________

ISO 9001:2000 QM S________

Quality Circle________

Kaizen__________

Juran Quality Improvement________

KTPA_______

24 What are your major successful products?

Product________

Generic / Brand Name__________

Customer Needs Satisfied________

Sales INR ______MILLION

25 Do you own any patents?

Yes__________No__________

26 If yes, for which products / process?

27 How often do you survey customers?

28 Dp you have any technological collaboration?

Yes______No________

29 If yes, since__________ Years

30 What kind of collaboration?

Technological Transfer_______

Alliance______________

Licensing________

Any Other__________

31 What federal regulatory approval and/or documentation do you need?

33 What business model do you have for performance excellence?

34 Any other comments / suggestions

DATE:

SIGNATURE

THANK YOU